OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President.
The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018). It is currently in phase 2 clinical trial in NSCLC.
The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies.
The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Espace Européen, 15 Chemin Du Saquin, Bât G.,france
- Phone
- 33 4 37 49 87 20
- or****@****ech.com
- Industry
- Research
- Website
- orega-biotech.com
- HQ
- Ecully, Auvergne Rhône Alpes
Orega Biotech Questions
Orega Biotech's helpline number is 33 4 37 49 87 20
Orega Biotech's website is orega-biotech.com
Orega Biotech's LinkedIn profile is https://fr.linkedin.com/company/orega-biotech
Orega Biotech has
7 employees.
View email and phone details for 7
employees at Orega Biotech.
Orega Biotech's industry is
Research
Orega Biotech's top competitors are
Sirius Neosight,
Netris Pharma,
Axoltis Pharma,
The White Bird,
Orphelia Pharma,
Biomunex Pharmaceuticals,
Ventuno Biotech,
Innate Pharma,
Initiative Octalfa,
Phaxiam Therapeutics.
Orega Biotech's support email address is orega@orega-biotech.com
Orega Biotech's categories are Research
Orega Biotech's founding year is 2010
